Denmark well placed in Nordic drug development
The Danish biotech and pharmaceutical industry has more candidate drugs in development than a number of European countries, including ones that are markedly larger.
Danish biotech and drug companies have, on a whole, a larger number of candidate drugs in their pipelines than Nordic neighbors Norway and Finland, while they lag somewhat behind Sweden, according to data compiled by Ernst & Young on behalf of MedWatch.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Danish biotech focuses on cancer
For abonnenter
